<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This review on <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is focused on the clinical <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> and variability, the new diagnostic criteria as delineated by an expert group in 2010, the current knowledge on the molecular and pathogenetic etiology, and the options of the medical and surgical treament </plain></SENT>
<SENT sid="1" pm="."><plain>Defined clinical findings, family history and mutations in the FBN1 gene only differentiate <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> from the other aortic syndromes </plain></SENT>
<SENT sid="2" pm="."><plain>The involvement of the cellular TGF-beta-signaling in pathogenesis allows new approach for medical treatment with ATR-blockers for which, however, evidence based indications are still lacking </plain></SENT>
<SENT sid="3" pm="."><plain>Finally, a suggestion is made how to arrange the diagnostic workup, appropriate treatment and follow-up of the Marfan patients in the Finnish health care </plain></SENT>
</text></document>